Archive for the ‘Gene Therapy Research’ Category

Part 3: Roundtable on Advanced Networking Initiatives in NC
Moderator: Joe Freddoso, MCNC John Moore, Senior Director Advanced Initiatives and Strategic Planning, MCNC Tracy Futhey -- CIO, Duke University Ilia Baldine -- Director, Networking Research Group, RENCI / UNC Henry Schaffer -- Professor Emeritus of Genetics and Biomathematics, NC StateFrom:MCNCvideosViews:0 0ratingsTime:11:17More inScience Technology

View original post here:
Part 3: Roundtable on Advanced Networking Initiatives in NC - Video

Part 2: Roundtable on Advanced Networking Initiatives in NC
Moderator: Joe Freddoso, MCNC John Moore, Senior Director Advanced Initiatives and Strategic Planning, MCNC Tracy Futhey -- CIO, Duke University Ilia Baldine -- Director, Networking Research Group, RENCI / UNC Henry Schaffer -- Professor Emeritus of Genetics and Biomathematics, NC StateFrom:MCNCvideosViews:0 0ratingsTime:09:16More inScience Technology

See the article here:
Part 2: Roundtable on Advanced Networking Initiatives in NC - Video

Part 1: Roundtable on Advanced Networking Initiatives in NC
Moderator: Joe Freddoso, MCNC John Moore, Senior Director Advanced Initiatives and Strategic Planning, MCNC Tracy Futhey -- CIO, Duke University Ilia Baldine -- Director, Networking Research Group, RENCI / UNC Henry Schaffer -- Professor Emeritus of Genetics and Biomathematics, NC StateFrom:MCNCvideosViews:0 0ratingsTime:10:19More inScience Technology

See the rest here:
Part 1: Roundtable on Advanced Networking Initiatives in NC - Video

Sequenced Pig Genome Creates Opportunities for Health Research
An international scientific collaboration that includes two CVM researchers is bringing home the bacon when it comes to potential animal and human health advancements, thanks to successfully mapping the genome of the domestic pig. The sequenced genome gives researchers a genetic blueprint of the pig. It includes a complete list of DNA and genes that give pigs their traits like height and color. Once all of the genetic information is understood, scientists anticipate improvements to the animal #39;s health as well as human health, as pigs and humans share similar physiologies. "With the sequenced genome we have a better blueprint than we had before about the pig #39;s genetics and how those genetic mechanisms work together to create, such as the unique merits in disease resistance," said Dr. Yongming Sang, research assistant professor in the Department of Anatomy and Physiology. For three years, Dr. Sang worked on the genome sequencing project with Dr. Frank Blecha, associate dean for the College of Veterinary Medicine and university distinguished professor of anatomy and physiology. A report of the international study appears as the cover story for the Nov. 15 issue of the journal Nature. To read more of the November issue of Lifelines, go to http://www.vet.k-state.eduFrom:KSUCVMViews:2 0ratingsTime:04:04More inEducation

See more here:
Sequenced Pig Genome Creates Opportunities for Health Research - Video

ROOFTOP MASSACRE (The Hidden)
#9658; #9658; #9658; Enjoy the video? Subscribe! bit.ly #9668; #9668; #9668; Download Here: http://www.hidden-source.com What is The Hidden? "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and traces of the experiments ...From:SeaNannersViews:302 2425ratingsTime:02:59More inGaming

Read more:
ROOFTOP MASSACRE (The Hidden) - Video

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today summarized ADCETRIS (brentuximab vedotin) data in relapsed Hodgkin lymphoma (HL) and other CD30-positive malignancies from multiple presentations at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Highlights include compelling survival data from long-term follow up in a pivotal clinical trial of ADCETRIS in relapsed or refractory HL and a retrospective comparison of overall survival among patients treated with ADCETRIS to those not treated with ADCETRIS following an autologous stem cell transplant (ASCT). In addition, data describe the activity and tolerability of ADCETRIS in the salvage HL setting from an investigator-sponsored trial and in relapsed patients age 60 or over with CD30-positive malignancies, including HL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL.

"There are more than a dozen data presentations at ASH evaluating the use of ADCETRIS in CD30-positive malignancies and we are very encouraged by both the broad application across multiple hematologic disease areas as well as the encouraging activity associated with ADCETRIS, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. The extensive investigator and corporate data presentations at ASH clearly demonstrate the important role ADCETRIS plays in the treatment of relapsed HL and systemic anaplastic large cell lymphoma and the promise of the role it potentially will play in additional future indications.

Long-term Survival Analysis of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma (Abstract #3689)

A pivotal, single-arm trial was conducted in 102 relapsed or refractory HL patients after ASCT to assess efficacy and safety of single-agent ADCETRIS. In addition, the trial was designed to determine duration of response, progression-free survival and overall survival. Enrolled patients had received a median of more than three prior chemotherapy regimens.

Data highlights from the long-term survival analysis in the pivotal trial were:

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant (Abstract #3701)

An independent retrospective comparison conducted by MD Anderson Cancer Center evaluated overall survival in 102 relapsed HL patients treated with ADCETRIS in a pivotal clinical trial compared to data from 756 relapsed HL patients treated at six international centers (Horning et al., 2008). The authors compared median overall survival, starting at the time of receiving an ASCT, among ADCETRIS treated patients to patients not treated with ADCETRIS. Key findings, which were highlighted in a presentation by Dr. Meghan Karuturi from MD Anderson Cancer Center, included:

Brentuximab Vedotin as a First Line Salvage Therapy in Relapsed/Refractory HL (Abstract #3699)

An investigator-sponsored trial was conducted to evaluate ADCETRIS as a salvage therapy for HL. Fourteen patients were evaluated for response and safety and all had relapsed or refractory HL after initial therapy with the chemotherapy regimens ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine hydrochloride, prednisone) or a combination of chemotherapy with or without consolidative radiation treatment. Patients were treated with ADCETRIS every three weeks for a maximum of four cycles. Data were presented by Dr. Robert Chen from City of Hope National Medical Center in Duarte, CA.

Read this article:
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive ...

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that results from two ongoing investigator-sponsored phase II clinical trials of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS has not been approved for use in the treatment of CTCL.

Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression (Abstract #797)

The ongoing phase II clinical trial is enrolling CTCL patients with mycosis fungoides (MF) or Sezary syndrome. Twenty patients have been enrolled to date with a median of six prior systemic therapies. The primary endpoint of the trial is clinical response rate. Secondary endpoints include correlation of clinical response with CD30 expression levels, duration of response and safety. The study was led by principle investigator Dr. Youn H. Kim from Stanford University School of Medicine in Stanford, CA, and was presented in an oral session. Key findings include:

Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders (Abstract #3688)

Data were presented from a phase II investigator-sponsored trial evaluating the use of ADCETRIS in CD30-positive CTCL patients, including lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL) or MF. The ongoing study is being conducted by Dr. Madeleine Duvic from The University of Texas MD Anderson Cancer Center in Houston, TX. Among 54 patients enrolled to date, 46 patients were evaluable at the time of analysis. The primary endpoint of the trial is to evaluate the safety and efficacy of ADCETRIS in CD30-positive CTCL. The key findings include:

Seattle Genetics and Millennium: The Takeda Oncology Company have initiated the ALCANZA trial, a randomized phase III clinical trial of ADCETRIS for relapsed CD30-positive CTCL patients. The trial is assessing ADCETRIS versus investigators choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with pcALCL or MF. The primary endpoint of the study is overall response rate lasting at least four months. Approximately 124 patients will be enrolled in the pivotal trial. The ALCANZA trial is being conducted under a Special Protocol Assessment agreement from the U.S. Food and Drug Administration (FDA). The study also received European Medicines Agency scientific advice.

About CTCL

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Cutaneous lymphomas are a category of non-Hodgkin lymphomas that primarily involve the skin. According to the Cutaneous Lymphoma Foundation, CTCL is the most common type of cutaneous lymphoma and typically presents with red, scaly patches or thickened plaques of skin that often mimic eczema or chronic dermatitis. Progression from limited skin involvement is variable and may be accompanied by tumor formation, ulceration and exfoliation, complicated by itching and infections. Advanced stages are defined by involvement of lymph nodes, peripheral blood and internal organs. According to published literature, up to 50 percent of CTCL patients lesions express CD30.

About ADCETRIS

See more here:
Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS® (Brentuximab Vedotin) in Cutaneous T ...

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma (HL) patients. The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. ADCETRIS is currently not approved for use in the front-line treatment of HL.

In the phase I trial, newly diagnosed patients received ADCETRIS concomitantly with either ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine) or AVD, which removes bleomycin from the regimen. At the end of front-line therapy, 24 of 25 patients (96 percent) treated with ADCETRIS plus AVD and 21 of 22 (95 percent) patients treated with ADCETRIS plus ABVD had a complete remission. None of the patients treated in the ADCETRIS plus AVD cohort experienced pulmonary toxicity, compared with an expected rate of pulmonary toxicity caused by ABVD alone of 10-25 percent. The trial was designed to establish the safety profile and maximum tolerated dose when adding ADCETRIS to ABVD or AVD. Antitumor activity was assessed as a secondary endpoint.

"For over 30 years, the standard of care for front-line HL has been a chemotherapy regimen called ABVD that has demonstrated a complete remission rate of 70 to 80 percent and is associated with considerable life-threatening toxicities. There is a significant need to identify better treatment options for patients in the front-line HL setting, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Our goal is to redefine front-line treatment of HL with the addition of ADCETRIS, and the encouraging results of this phase I trial clearly support this goal and provide rationale for the ongoing ADCETRIS phase III trial in this setting."

Front-line Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma (Abstract #798)

In this open-label, multicenter trial, cohorts of patients received an escalating dose of ADCETRIS (0.6 milligrams per kilogram (mg/kg), 0.9 mg/kg, 1.2 mg/kg) every two weeks concomitantly with ABVD or a dose of 1.2 mg/kg every two weeks concomitantly with AVD.

Fifty-one patients were enrolled in the phase I study and 47 were evaluable for response at trial completion. The 47 evaluable patients included 25 in the ADCETRIS plus AVD cohort and 22 in the ADCETRIS plus ABVD cohorts. All patients were previously untreated and 45 percent had Stage IV HL. The median age of patients across all cohorts of the trial was 33 years. Key findings, which were highlighted in an oral presentation by Dr. Stephen Ansell, Professor of Medicine, Division of Hematology, from the Mayo Clinic, included:

For decades researchers have strived to improve our front-line HL treatment strategy by enhancing the activity of traditional chemotherapy regimens while reducing the significant toxicities and long-term side effects of such regimens, said Stephen Ansell,M.D., Ph.D., Professor of Medicine, Division of Hematology, Mayo Clinic. There is a significant need to identify better treatment options for patients in the front-line setting. With a complete response rate of 96 percent and a manageable safety profile, data from this trial support further evaluation of ADCETRIS administered concomitantly with AVD in previously untreated HL patients to potentially improve the current standard of care.

Seattle Genetics and Millennium: The Takeda Oncology Company have initiated a phase III clinical trial in advanced stage front-line HL patients. The randomized trial is comparing progression-free survival in patients receiving ADCETRIS in combination with AVD to patients receiving ABVD alone. For more information about the trial visit http://www.seattlegenetics.com or http://www.clinicaltrials.gov.

About ADCETRIS

Originally posted here:
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ...

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today highlighted clinical data from two antibody-drug conjugate (ADC) programs in development by Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) that utilize Seattle Genetics technology. The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Phase I data from both ADCs, an anti-CD22 ADC (DCDT2980S, RG7593) and an anti-CD79b ADC (DCDS4501A, RG7596), demonstrated antitumor activity in relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) patients at generally well-tolerated doses. These ADC programs are currently being evaluated in a phase II clinical trial for patients with relapsed or refractory B-cell NHL.

Genentechs phase I data and their advancement of these two ADCs into phase II clinical development, as well as their utilization of our technology in six other clinical-stage programs,illustrates their commitment to ADCs as an innovative, targeted approach to treat cancer,saidEric Dobmeier, ChiefOperatingOfficer of Seattle Genetics. Across our ADC collaborations, there is broad potential for our industry-leading technologyto address thesignificant needformore effective and better tolerated treatment options.

Anti-CD22-MMAE and anti-CD79b-MMAE are ADCs designed to deliver potent cytotoxic treatment to targeted cells with improved tolerability. With over a decade of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cytotoxic agents, such as monomethyl auristatin E (MMAE), and stable linker systems that attach these cytotoxic agents to the antibody. Seattle Genetics linker systems are designed to be stable in the bloodstream and release the potent cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity. ADCETRIS (brentuximab vedotin) is the first drug approved utilizing Seattle Genetics ADC technology.

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (Abstract #56)

A phase I clinical trial is being conducted to evaluate the safety and activity of DCDS4501A in patients with relapsed or refractory B-cell NHL. DCDS4501A is an ADC consisting of an anti-CD79b monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics ADC technology. In this analysis, 47 patients were evaluable for safety and 32 were evaluable for efficacy.

Key findings included:

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (Abstract #59)

A phase I clinical trial is being conducted to evaluate the safety and activity of DCDT2980S in patients with relapsed or refractory B-cell NHL. DCDT2980S is an ADC candidate consisting of an anti-CD22 monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics ADC technology. In this analysis, 43 patients were evaluable for safety and 33 were evaluable for efficacy.

Key findings included:

View original post here:
Seattle Genetics Highlights Data Presentations from Genentech ADC Collaborator Programs at ASH Annual Meeting

TAINAN, Taiwan--(BUSINESS WIRE)--

The Society of Genetics, Genomics and Computational Biology had officially set up an education center at National Cheng Kung University (NCKU), southern Taiwan, to facilitate genetics and computational biology studies and to promote international interaction and communication in these fields, the university announced Dec. 5.

Dr. Chi-Chuan Hwang, chair of the education center, said that in order to promote research in these areas, the society had set up different teams based on different job contents, including the biology database team, the non-biological resource team, the computational biology skills team, the genetics team, the biotechnology team and the talent development team, and assigned people from the societys member countries to these teams.

The education center established at NCKU is focusing on talent cultivation, said Hwang, adding that the center hopes to recruit young students from different fields, including biology, medicine and engineering, in order to conduct interdisciplinary research.

With Fujitsu providing the hardware equipment, the first step taken by the education center was to ensure that the new software is capable of handling huge amount of data, and also to carry out the construction of gene pool and genome sequencing alignment, according to Hwang.

The Genomics and Bioinformatics course held on Dec. 3 was the first task of this education center.

Japans National Institute of Genetics (NIG) Deputy Director Takashi Gojobori, who is also Visiting Distinguished Chair Professor of NCKU, pointed out that efforts will be focused on the research of the variation of native species in Taiwan, especially the collection and analysis of seed gene pool, to build a complete gene sequencing database and also conduct a complete gene sequencing analysis on the collected genes.

Gojobori expected that these efforts would enhance NCKUs research capability and academic standards related to non-model species and biological diversity.

He hoped that by gathering different research capability, every team member will be able to make the greatest possible contribution to the conservation and protection of agriculture, ocean and natural environment.

The center will serve as an important platform for international interaction and communication in these fields, according to Gojobori, whose main purpose is not only to develop and nurture talent for research, but also to recruit domestic and foreign scholars to conduct education training and organize idea exchange sessions between member countries.

View post:
NCKU Sets up Genetics, Genomics, Computational Biology Education Center

Philippe Moullier, directeur scientifique Atlantic Gene Therapy #65279;
From:TelethontvViews:0 0ratingsTime:05:34More inNonprofits Activism

The rest is here:
Philippe Moullier, directeur scientifique Atlantic Gene Therapy - Video

Innovation Presentation - Cancer Gene Therapy Project
NSW Health:bit.ly Media Release:bit.ly The Minister for Health, Jillian Skinner, hosted a community health forum in Parramatta on Wednesday 26 September 2012 to give Greater Western Sydney residents the chance to have their say on the future of health services in their community.From:NewSouthWalesHealthViews:0 0ratingsTime:06:48More inNonprofits Activism

The rest is here:
Innovation Presentation - Cancer Gene Therapy Project - Video

Ramsey Majzoub explains Gene Therapy Research conducted in the Safinya Group at UCSB
From:jennylei8Views:0 0ratingsTime:03:21More inPeople Blogs

See original here:
Ramsey Majzoub explains Gene Therapy Research conducted in the Safinya Group at UCSB - Video

Help Hemophilia of Georgia fund research for a cure
Families affected by hemophilia are anxiously waiting to find out if current gene therapy research will result in a cure. In this video, two fathers share what a cure would mean to their familiesFrom:HemophiliaOfGeorgiaViews:1 0ratingsTime:01:23More inNonprofits Activism

See the original post:
Help Hemophilia of Georgia fund research for a cure - Video

Melanoma, how can we have an earlier diagnosis? - Profesor Dréno
Interview of Professor Brigitte Dréno Vice Dean in charge of Research Faculty of Medicines Department of Dermato Cancerology Director Cell and Gene Therapy Unit Nantes Hospital University Giving her opinion on how to have an earlier diagnosis for melanoma.From:UVDAMAGELRPViews:2 0ratingsTime:03:45More inEducation

Go here to see the original:
Melanoma, how can we have an earlier diagnosis? - Profesor Dréno - Video

PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--

The Vaccine and Gene Therapy Institute of Florida (VGTI Florida), a leading nonprofit immunological research institute, is pleased to announce the appointment of Ted M. Ross, Ph.D., as Program Director. Dr. Ross will explore new vaccine technologies intended to protect against all strains of seasonal influenza. Such a vaccine could potentially eliminate the need for seasonal flu shots.

Traditionally, the flu vaccine is a mixture of inactive influenza viruses. However, Dr. Ross is taking a novel approach by examining the use of a synthetic vaccine created from genetic sequences of many different flu viruses. Dr. Ross previously used this method to produce a vaccine against the H5N1 virus, commonly known as the bird flu. The vaccine, well-tolerated in pre-clinical trials, successfully protects against known strains of bird flu. Dr. Ross and his VGTI Florida colleagues are applying similar strategies to fight other serious viruses such as West Nile Virus, Dengue and HIV Type 1 (HIV-1).

The holy grail of influenza vaccine research is a vaccine that protects against all influenza strains, avoiding the need for annual vaccinations, said Jay Nelson, Ph.D., founder and Executive Director, VGTI Florida. Were genuinely excited that Dr. Ross has joined us. His extensive background in immunology and microbiology will further benefit our efforts to develop vaccines that can help people with influenza, especially the elderly, added Dr. Rafick Skaly, Chief Scientific Officer and Co-Director of the institute.

Most recently, Dr. Ross was an Associate Professor, University of Pittsburgh School of Medicine, where he served in the Microbiology and Molecular Genetics department and was a full member of the Center for Vaccine Research. Prior to that, he was an Assistant Professor in the Department of Microbiology and Immunology at East Carolina University, School of Medicine in North Carolina.

Dr. Ross has co-authored numerous scientific articles published in journals such as Nature Immunology, The Journal of Virology, Journal of Infectious Disease, Vaccine, and the Proceedings of the National Academy of Sciences. He is a member of the American Society for Virology, American Society of Microbiology, Sigma Xi, International Society of Vaccines, and others. He holds B.S. and M.S. degrees from the University of Arkansas in Zoology and Microbiology, respectively. Dr. Ross earned his Ph.D. from Vanderbilt University in Microbiology & Immunology. Additionally, he was a Postdoctoral Fellow in HIV Research at Duke University and a Senior Research Associate in HIV Vaccine Research at Emory University.

VGTI Florida

VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer and HIV/AIDS. VGTI Florida is an independent non-profit 501 (c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit http://www.VGTIFL.org.

See the original post:
Dr. Ted Ross Joins the Vaccine & Gene Therapy Institute of Florida as Program Director

STAMFORD, Conn.--(BUSINESS WIRE)--

Alliance for Cancer Gene Therapy (ACGT), the nations only non-profit organization dedicated exclusively to funding cell and gene therapy research for cancer, is excited to play a major role in the recent leukemia study pioneered by scientists at the Perelman School of Medicine at the University of Pennsylvania. ACGT was the initial funding arm for the study using immune-mediated gene therapy for leukemia and lymphoma. This study illustrates the successful and sustained demonstration of how gene therapy uses the bodys own T-cells and turns them into weapons aimed directly at cancer.

Initial ACGT grants were awarded in 2004 to Dr. Carl June of the Abramson Family Cancer Research Institute at the University of Pennsylvania, and to Dr. Michel Sadelain, of Memorial Sloan-Kettering Cancer Center, Gene Therapy & Gene Expression Laboratory in New York City. Preliminary results were issued by Dr. Carl June and the University of Pennsylvania in August 2011, with additional results released this week and presented by Dr. Carl June at the American Society of Hematologys Annual Meeting and Exposition being held in Atlanta, Georgia.

The clinical trial participants, all of whom had advanced cancers, included ten adult patients with chronic lymphocytic leukemia, were treated at the Hospital of the University of Pennsylvania (HUP) and two children with acute lymphoblastic leukemia were treated at the Childrens Hospital of Philadelphia (CHOP). Two of the first three patients treated with the protocol at HUP whose cases were detailed in The New England Journal of Medicine and Science Translational Medicine in August 2011 remain healthy and in full remission more than two years after their treatment, with the engineered cells still circulating in their bodies. Currently, nine out of 12 of the participants show their disease in remission.

The discovery of successful cancer gene therapy treatments are what my husband and I hoped for when we founded ACGT a decade ago, noted Barbara Netter, president and co-founder of the Alliance for Cancer Gene Therapy. We knew it would be an uphill battle. ACGT was the only organization willing to take the risk when others were not. With federal funds decreasing, and the realization that pharmaceutical companies will not participate in the research phase until marketable and mass-produced treatments are created, we seized the chance to make a difference. My late husband Edward Netter (1932-2011), was a true visionary in the field of medical research. He would be so thrilled by the progress ACGT has made possible.

ACGT is currently funding 17 clinical trials in cancer cell and gene therapy targeting numerous types of cancers. Since its inception, ACGT has awarded more than $23 million in grants to 39 investigators to treat 11 different types of cancer. In 2012, ACGT also awarded a $500,000 grant to a clinical translational study on pancreatic cancer and has great expectations for its outcome. In ACGTs 2011 grant cycle, 87 scientists from throughout the U.S. responded with grant applications for ACGTs Young Investigator Grants, making 2011 one of the most sought-after funding year in ACGT history. The ACGT funded clinical studies are already showing promise, especially in the treatment of leukemia, lung, melanoma and prostate cancers.

It is so exciting that the pathfinder role ACGT played by provided the seed money for the University of Pennsylvania trial has led to these stunning successes for leukemia treatment, said Dr. Savio Woo, chairman of ACGTs Scientific Advisory Council, and founding Chair of the Department of Gene and Cell Medicine at Mt. Sinai School of Medicine in New York City.

Woo noted that 100 percent of all funds donated to ACGT go directly toward funding innovative cancer gene therapy research grants. ACGTs Scientific Advisory Council, which comprises some of the best scientific minds and thought leaders with major U.S. medical institutions, oversee all phases of the ACGT grant process. Through this rigorous review, ACGT is able to identify and fund studies with the most potential for positive and innovative outcomes for treating cancer using cell and gene therapy.

The University of Pennsylvanias initial study was funded primarily by ACGT. The most recent clinical trial was also supported by ACGT, the Leukemia & Lymphoma Society (Dr. June is the leader of one of the LLSs grants), and the National Institutes of Health. In addition, Novartis announced this summer that it would fund additional research at the University of Pennsylvania to further study the immunotherapies and has acquired exclusive rights to market the treatment.

Alliance for Cancer Gene Therapy (ACGT) is the nations only non-profit dedicated exclusively to cell and gene cancer therapy research. One hundred percent of all contributions to ACGT go directly to research and fund grants with leading scientists in the U.S., representing such institutions as Harvard Medical School, Johns Hopkins University School of Medicine, Mayo Clinic, St. Judes Childrens Hospital, Duke University, The Salk Institute, University of Pennsylvania, Memorial Sloan-Kettering, Stanford University, Dana Farber Cancer Center, University of California San Diego, University of Pittsburgh, and the University of Chicago. A rigorous grant review by Scientific Advisory Council ensures the most promising projects are rewarded. To learn more about the leukemia study at the University of Pennsylvania, and about the Alliance for Cancer Gene Therapy (ACGT), visit http://www.acgtfoundation.org or call 203.358.8000.

More:
Alliance for Cancer Gene Therapy Funds Promising Leukemia Study – Patients in Remission More Than Two Years after Gene ...

Gordon Camp (Parkinson #39;s Disease) Stem Cell Therapy
New Project 46From:OmarGonzalezMDViews:0 0ratingsTime:06:29More inScience Technology

Original post:
Gordon Camp (Parkinson's Disease) Stem Cell Therapy - Video

Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage
Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear!From:Deals2uTVViews:0 0ratingsTime:02:01More inHowto Style

The rest is here:
Stem Cell Therapy - Let Your Own Stem Cells Make Wrinkles Virtually Disappear! Free postage - Video

"Labrum Tear is now Being Treated With Cell Therapy at the Center for Regenerative Medicine Using," according to Dr. Farshchian MD, medical director for the center for regenerative medicine.

(PRWEB) December 11, 2012

Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites.

The labrum is a fibrocartilaginous rim which attaches to the acetabulum cavity (This is where the hip joint is located). Its job is to protect the femur (or the hip bone) and decrease any unevenness in its surface. The labrum is important since it decreases stresses between the joint surfaces, by producing a "sealing effect". It acts as a bumper which deepens the joint socket and helps keep the head of femur in place.

The vascularity or blood flow is minimal which is not a good thing at all, this factor makes self healing hard to come by.

Although not very specific the FABRE test (see picture) could be positive in presence of a tear. Here the examiner is anchoring patient's ankle against the opposite knee and pressing on the knee reproducing pain and tenderness in the anterior hip (medical lingo: front).

MRI with contrast is a more specific test allowing the physician to actually visualize the tear.

The condition is painful and annoying since it interferes with activities, This entity may be a risk factor future arthritis and problems to follow. This condition is not common at all but the several times that I have seen it it has involved aggressive physical activity such as jumping on a trampoline or sports injury.

U.S.A. based physician, Dr. Farshchian is a medical author, humanitarian, and active republican member. He is best known for coining the term orthopedic regenerative medicine. Dr. Farshchian is recognized as a leading authority in the new clinical science of regenerative medicine. He is also a Television personality currently hosting "The Arthritis Show".

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center's expertise is in treatment of conditions of spine, knees , shoulders , and other cartilage damages. They have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Their team includes health professionals organized around a central theme. their website is http://www.arthritisusa.net

More here:
Dr. Farshchian: Labrum Tear is Now Being Treated With Cell Therapy at the Center for Regenerative Medicine Using

Autologous cell therapy is now being used to help with neck pain at The Center for Regenerative Medicine, according to Dr. Farshchian, the medical director for the center for Regenerative medicine.

(PRWEB) December 10, 2012

All the interconnected structures that give your neck its incredible range of motion are subject to the wear-and-tear damage of arthritis and the over extension injuries of whiplash. Neck pain may result from abnormalities in the soft tissues - the muscles, ligaments, and nerves - as well as in bones and joints of the spine. The most common causes of neck pain are soft tissue abnormalities due to injury or prolonged wear and tear. In rare cases, infection or tumors may cause neck pain. In some people, neck problems may be the source of pain in the upper back, shoulders or arms.

Degenerative diseases that cause neck pain include osteoarthritis and rheumatoid arthritis. Osteoarthritis usually occurs in older people as a result of wear of the joints between the bones in the neck. Rheumatoid arthritis can cause destruction of the joints of the neck. Both of these major types of arthritis can cause stiffness and pain.

Cervical disk degeneration also can cause neck pain. The disk acts as a shock absorber between the bones in the neck. In cervical disk degeneration (typically age 40 onwards), the normal gelatin-like center of the disk degenerates and the space between the vertebrae narrows. As the disk space narrows, added stress is applied to the joints of the spine causing further wear and degenerative disease.

The cervical disk may also protrude and cause pressure on the spinal cord or nerve roots when the rim of the disk weakens. This is known as a herniated cervical disk. Because the neck is so flexible and because it supports the head, it is extremely vulnerable to injury. Motor vehicle or diving accidents, contact sports, and falls may result in neck injury. The regular use of safety belts in motor vehicles can help to prevent or minimize injury. A "rear end" automobile collision may result in hyper extension, a backward motion of the neck beyond normal limits, or hyperflexion, a forward motion of the neck beyond normal limits. Most common injuries are to the soft tissues, i.e., muscles and ligaments. Severe injury with fracture or dislocation of the neck may damage the spinal cord and cause paralysis.

Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites.

Much less common causes of neck pain include tumors, infections, or congenital abnormalities of the vertebrae. There is also the emotional part, I mean why would the pain get worse with stress and get better with less stress, this must be emphasized when treating patient with neck pain other wise the job is not done. Why the tingling of the fingers? this is because of nerve conduction and dermatomes. Dermatomes are located on the anterior body and the posterior body and are consecutive in the neck and torso regions. Development of the peripheral nervous system will produce a pattern of skin innervated by cutaneous neurons of a certain spinal or cranial nerves. These are called dermatomes and represent specific regions of nerve reception of sensory impulses. The pattern of the dermatome is of major clinical significance when a physician desires to treat a particular portion of the body. For instance the gentleman discussed in the above case having numbness in the index finger as well as his thumb (refer to the picture) may need to be treated specifically at the level of C6-C7.

U.S.A. based physician, Dr. Farshchian is a medical author, humanitarian, and active republican member. He is best known for coining the term "orthopedic regenerative medicine." Dr. Farshchian is recognized as a leading authority in the new clinical science of regenerative medicine. He is also a Television personality, currently hosting "The Arthritis Show."

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center's expertise is in treatment of conditions of spine, knees , shoulders , and other cartilage damages. They have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Their team includes health professionals organized around a central theme. their website is http://www.arthritisusa.net

Read this article:
Dr. Farshchian: Autologous Cell therapy is Now Being Used to Help with Neck Pain at The Center for Regenerative Medicine

Autologous cell therapy is now being used to help with avascular necrosis at the Center for Regenerative Medicine, according to Dr. Farshchian.

Miami, Fl (PRWEB) December 10, 2012

Avascular necrosis can be quite devastating, and lead to total loss of the ankle joint with arthritis, deformity and pain. Loss of blood supply to the bone can be caused by an injury (trauma-related avascular necrosis) When a joint is injured, as in a fracture or dislocation, the blood vessels may be damaged. This can interfere with the blood circulation to the bone and lead to trauma-related avascular necrosis. Studies suggest that this type of avascular necrosis may develop in more than 20 percent of people who dislocate their hip joint.

Some medicines such as Corticosteroids are commonly used to treat diseases in which there is inflammation, such as systemic lupus erythematosus, rheumatoid arthritis, and vasculitis. Studies suggest that long-term, systemic (oral or intravenous) corticosteroid use is associated with 1/3 of all cases of non-traumatic avascular necrosis. The current theory is corticosteroids may interfere with the body's ability to break down fatty substances. These substances then build up in and clog the blood vessels, causing them to narrow. This makes less blood to gets to the bone. Excessive alcohol use and corticosteroid use are two of the most common causes of non- traumatic avascular necrosis. In people who drink an excessive amount of alcohol, fatty substances may block blood vessels causing a decreased blood supply to the bones that results in avascular necrosis.

Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites.

Other risk factors or conditions associated with non-traumatic avascular necrosis include Gaucher's disease, pancreatitis, radiation treatments and chemotherapy, and blood disorders such as sickle cell disease. Avascular necrosis strikes both men and women and affects people of all ages. It is most common among people in their thirties and forties. Depending on a person's risk factors and whether the underlying cause is trauma, it also can affect younger or older people.

In the early stages of avascular necrosis, patients may not have any symptoms. As the disease progresses, however, most patients experience joint painat first, only when putting weight on the affected joint, and then even when resting. Pain usually develops gradually and may be mild or severe. If avascular necrosis progresses and the bone and surrounding joint surface collapses, pain may develop or increase dramatically. Pain may be severe enough to limit the patient's range of motion in the affected joint. The period of time between the first symptoms and loss of joint function is different for each patient, ranging from several months to more than a year.

U.S.A. based physician, Dr. Farshchian is a medical author, humanitarian, and active republican member. He is best known for coining the term "orthopedic regenerative medicine." Dr. Farshchian is recognized as a leading authority in the new clinical science of regenerative medicine. He is also a Television personality, currently hosting "The Arthritis Show."

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center's expertise is in treatment of conditions of spine, knees , shoulders , and other cartilage damages. They have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Their team includes health professionals organized around a central theme. their website is http://www.arthritisusa.net

Marty Eugene http://www.arthritisusa.net 305 8668384 Email Information

The rest is here:
Dr. Farshchian: Autologous Cell Therapy is Now Being Used to Help with Avascular Necrosis at The Center for ...

SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- The Global Institute Of Stem-cell Therapy And Research (GIOSTAR) announced today a collaborative treatment plan to serve the local population suffering from a genetic disease, Sickle Cell Anemia. President and CEO, Mr. Deven Patel and his team met with Honorable Chief Minister Shri Arjun Munda of State of Jharkhand, India in November 2012 to address the local population's medical needs.

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16184.

As a follow-up, a government delegation representing the state of Jharkhand, India; Chief Minister, Principal Health Secretary, Chief Secretary and many other officials are visiting GIOSTAR in San Diego on December 14, 2012 to finalize the proposed two (2) billion U.S. dollar contract to be serviced over the next 15 years.

Bob Filner, Mayor of San Diego and City Council Members are among the invited guests for this state visit along with representatives from Belize and the island nation of Saint Vincent and the Grenadines.

Two hundred (200) jobs are estimated to be created in San Diego and it is expected that the dialog would include an economic development program between City of San Diego and State of Jharkhand, India.

GIOSTAR is a Global Private Funding (Global) incubated company. "Global is a private equity firm that focuses on funding projects and initiatives that are job-creation centric rather than just profit centric. We believe that a venture that draws the best minds and hearts to a unified goal, driven by a unified vision tends to be far stronger and less prone to failure than one driven by just profit. We invest in people, not the business," said Dr. Sam Senev, Chairman and CEO of Global. Senev added that GIOSTAR is a showcase client focused on both serving mankind through quality of life and job creation.

GIOSTAR, headquartered in San Diego, California (USA), was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world. We are the leaders in developing innovative stem cell based technology.

The Chairman and Cofounder of GIOSTAR, Dr. Anand Srivastava and our team of scientists and clinicians have been associated with leading universities and research institutions throughout USA. GIOSTAR team has extensive research and clinical experience in the field of Stem cell, which is documented by several publications in revered scientific journals.

GIOSTAR in July 2011, inaugurated the world's first dedicated stem cell treatment hospital, a 125-bed, contemporary facility with the most advanced on-site stem cell laboratory. This hospital is fully operational. GIOSTAR is developing the world's largest, a three hundred thousand square-foot (300,000SF) state-of-the-art, Stem Cell Treatment Hospital in the Surat Civil Hospital Campus in collaboration with the government of Gujarat. Negotiations are ongoing with China, Philippines, Bahamas, Belize, Thailand, Ukraine and the Middle East to open regional stem cell treatment hospitals and satellite clinics throughout those countries and regions. "We are expanding the GIOSTAR footprint and is in negotiations to open locations near Austin Texas, Phoenix Arizona, and Savannah South Carolina" said Michael Andersen, Vice President of Venture Management at Global. Global and Empyrean West, EB-5 administrators, plan to invest over one hundred and eighty million ($180M) in economic development investments for GIOSTAR projects.

The Global Institute of Stem Cell Therapy and Research company logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16183.

More here:
Photo Release -- GIOSTAR and the Government of India to Enter $2 Billion Stem Cell Therapy Program - Official State ...

LONDON (Reuters) - U.S. biotechnology group Amgen Inc has agreed to buy unlisted Decode Genetics, a pioneer in hunting down genes linked to disease, for $415 million in cash to boost its drive to develop better targeted drugs.

Founded in 1996, Decode blazed a trail in personal genomics by trawling Iceland's unique genetic heritage, which has changed little since the Vikings arrived more than 1,000 years ago, to work out the links between gene variants and common diseases.

But it failed to live up to early expectations after going public in 2000 and filed for bankruptcy protection in 2009, weighed down by debts after 13 years of failing to make a profit, before re-emerging as a privately owned company.

Amgen and Decode said on Monday that the transaction did not require regulatory approval and was expected to close before the end of 2012.

As part of Amgen, Decode's scientists will help in the task of ensuring that experimental medicines hit the right spot. Their know-how should allow Amgen to identify promising new avenues earlier and close down dead-ends more quickly.

"This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets, while avoiding investments in programs based on less well-validated targets," Amgen Chief Executive Robert Bradway said.

PERSONALISED MEDICINE

UBS analysts said that the purchase, which will be funded by cash held offshore, was not surprising given that Amgen has key experimental drugs in its pipeline that were identified by human genetics work, including AMG 145 for heart disease and the bone drug romosozumab.

Understanding the genetic basis of disease has become increasingly important in drug discovery as the pharmaceutical industry shifts to developing personalized medicine that is suited for a patient's particular genetic profile.

It is an area where Decode has extensive experience and its scientists have published prolifically on genetic mutations linked to a range of diseases including cancer, heart conditions and schizophrenia.

More:
Amgen buys Icelandic gene hunter Decode for $415 million

1. Introduction and Overview- Biotechnology: Panacea or Pandora #39;s Box NQ
Given the rapid recent advances in genomics, agriculture, transgenic biology, stem cell research and other related areas of biotechnology and a prediction that these fields will continue to mature and become increasingly more sophisticated, there is an growing need to create an informed and educated student in this area. We believe that a working knowledge of DNA, genetics, and biotechnology has become as fundamental to a basic education as an understanding of the solar system. In addition, biotechnology fields offer students career opportunities which is best recognized early in their academics so that they can make the appropriate choices to be best prepared. The rise of recent controversy and misconceptions about many areas of biotechnology including GMOs in food, vaccines and vaccination, personalized medicine, stem cell research and many other topics creates a growing educational challenge. The introduction of a general education course which concentrates on evidence based knowledge on biotechnology and is developed for a general audience with a large potential enrollment is designed to meet that challenge. In turn our experience shows that such a course serves to recruit new scientists and other participants into the careers in the emerging new fields of biotechnology and stimulates further interest in STEM related disciplines. The courses in this series have been established in the curriculum over the past several years with high student demand and interest. Given ...From:Albert KauschViews:0 0ratingsTime:01:05:12More inScience Technology

Excerpt from:
1. Introduction and Overview- Biotechnology: Panacea or Pandora's Box NQ - Video